Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

20 January 2022 Gilead Sciences has sued an array of pharmaceutical suppliers and distributors accusing them of forming a ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Notable insider trades include Parsey Merdad, Chief Medical Officer at Gilead Sciences, Inc. (GILD), who sold 21246 shares on Sep 12 ’24, at $84.5 each, totaling $1.80 million. On Sep 12 ’24, Mercier ...

Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.

Gilead Sciences (GILD) closed at $83.08 in the latest trading session, marking a -0.1% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.03%. Meanwhile, the Dow ...

Shares of Gilead Sciences Inc. GILD dropped 0.13% to $83.05 Tuesday, on what proved to be an all-around mixed trading session ...